NCT01018563 2021-12-08
An Open Label Extension Study of the Efficacy of MORAb-003
Morphotek
Phase 2 Terminated
Clinical Trials
5 trialsNCT02289950 2021-09-02
A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
Eisai Inc.
Phase 2 Completed
NCT01218516 2020-08-20
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
Morphotek
Phase 2 Completed
NCT00738699 2017-03-30
FAR-122
Morphotek
Phase 2 Terminated
NCT00318370 2015-09-09
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
Morphotek
Phase 2 Completed